Product Information
EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES) is a brand product labeled by Eli Lilly and Company, priced at $612.5164 per ML under NDC 00002311509. Its NADAC has been published 350 times since Jan 22, 2020.
Strength
100 mg/mL
Manufacturer
Eli Lilly and CompanyNDC
00002311509
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
GALCANEZUMABApproval Type
Biologic (BLA)
FDA Application
BLA761063On Market Since
6/4/2019
Price Statistics
The NADAC for EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES) has been published 350 times since Jan 22, 2020, and over the history we have for it it has risen 32.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $612.5164 per ML |
|---|---|
| All-time high | $612.9103 (Jul 15, 2026) |
| All-time low | $461.0067 (Jan 22, 2020) |
| 52-week high | $612.9103 |
| 52-week low | $594.2803 |
| Median price | $545.9158 |
| Average price | $545.3426 |
| Largest weekly change | +5.0% (Jan 8, 2025) |
| Weeks tracked | 350 |
| Tracking since | Jan 22, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the galcanezumab-gnlm market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
galcanezumab-gnlm market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES)?
The current National Average Drug Acquisition Cost (NADAC) for EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES), manufactured by Eli Lilly and Company, is $612.5164 per ML (NDC 00002311509), effective Sep 30, 2026.
How has the price of EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES) changed over time?
Over the history we have for it, the NADAC for EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES) has risen 32.9%. It has been tracked across 350 weekly CMS publications since Jan 22, 2020.
What are the highest and lowest recorded NADAC prices for EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES)?
Since Jan 22, 2020, the NADAC for EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES) has ranged from a low of $461.0067 (Jan 22, 2020) to a high of $612.9103 (Jul 15, 2026), with a median of $545.9158 per ML.
Are there cheaper alternatives to EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES)?
No other NADAC-published product currently shares the active ingredient and strength of EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES) in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES)?
EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES) (NDC 00002311509) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.